nature portfolio

Corresponding author(s):	Luke Alphey
Last updated by author(s):	Dec 8, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

⋖.	トつ	1	C	۲ı	CS
J	ιa	ı.	0	L I	LJ

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
	\boxtimes	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	\boxtimes	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	\boxtimes	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	\boxtimes	A description of all covariates tested
	\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
	\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>

Data collection

Complete details of the model available in Supplementary information S2. All Matlab scripts used in the mathematical modeling are freely available via the Open Science Framework (osf.io/bp4yh).

Data analysis

Amplicon-Seq analysis

Sequencing reads generated from the amplicon sequencing were analysed using the CRISPRessoBatch tool in CRISPResso2 (610 with the following script:

CRISPRessoBatch --batch_settings [batch file name] -a

Modification rates of nucleotides surrounding the sgRNA recognition sites were plotted with GraphPad Prism 9. In cases of insertions, CRISPResso2 counts the nucleotides on both sides of the insertion as mutant in the output file. In this case rates were calculated using only the 'insertion left' dataset, to avoid counting the same mutation twice. Rates of unmodified nucleotides were calculated by simple subtraction (1 - modification rate) and subsequently plotted with GraphPad Prism 9.

Phenotype data analysis

We carried out all phenotype analyses using R version 3.6.2 (R Development Core Team) (62). Data sets were summarized using 'tidyverse' (63) and figures generated using 'ggplot2' (64). Likelihood ratio tests carried out with 'DescTools' (65). Generalized linear mixed model analyses were carried out using 'Ime4' (66), and summarized with 'emmeans' (67) and 'sjPlot' (68), model residuals were checked for

violations of assumptions using the 'DHARMa' package (https://github.com/Philip-Leftwich/Population-level-demonstration-of-multiplex-drive-Aedes-aegypti) (69).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Blinding

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All raw reads from amplicon-Seq generated in this study were submitted to NCBI SRA with the accession number PRJNA741076 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA741076/). Addgene plasmid # 52891; http://n2t.net/addgene:52891; RRID:Addgene_52891. Plasmid sequences are available from NCBI OP728003 https://www.ncbi.nlm.nih.gov/nuccore/OP728004, OP728005 https://www.ncbi.nlm.nih.gov/nuccore/OP728005. The remaining data generated for this study is available in the supplemental dataset 1 file and source data are provided with this paper.

Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation),

Research involving human participants, their data, or biological material

Blinding was not performed as none of the data collected were subjective.

<u>and Sexual Orientation</u> ar	id <u>race, ethnicity and racism</u> .		
Reporting on sex and g	ender Not applicable		
Reporting on race, ethi other socially relevant groupings	nicity, or Not applicable		
Population characteris	Not applicable		
Recruitment	Not applicable		
Ethics oversight	Not applicable		
Note that full information o	n the approval of the study protocol must also be provided in the manuscript.		
Field-specif	ic reporting		
· · · · · · · · · · · · · · · · · · ·	ow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
X Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences		
For a reference copy of the doc	ument with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life science	es study design		
All studies must disclose	on these points even when the disclosure is negative.		
	sic power analysis was performed and determined that for 0.8 power, we should analyse at least 200 for a 10% difference between ritance rates.		
Data exclusions No d	ata were excluded from analysis.		
(F1) v trans heter	kmosgRNAs adult females and males (at least 20) were crossed to the opposite sex bgcn-Cas9 adults to generate trans-heterozygous adults (F1) with each mating event representing a biological replicate and all replicates were successful. For initial assessments of kmosgRNAs transgene inheritance, F1 adults were pooled into groups of at least 5 trans-heterozygous females or males and crossed to WT. All F1 trans-heterozygotes displayed a mosaic eyed phenotype. All progeny (F2) were screened for presence of each transgene and eye color phenotype. Multiple replicate F1 of each genotype/phenotype were randomly selected for each cross. No replicates were excluded.		
	osquitoes were screened for presence of the fluorescent markers indicating each transgene and separated by sex for mating. Trans-		

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems	Methods			
n/a Involved in the study	n/a Involved in the study			
Antibodies	ChIP-seq			
Eukaryotic cell lines	Flow cytometry			
Palaeontology and archaeology	MRI-based neuroimaging			
Animals and other organisms				
Clinical data				
Dual use research of concern				
∑				
Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research				
	Aedes aegypti Liverpool strain was used, adults were crossed when 2-3 days post eclosion and allowed to mate for at least 2 days prior to bloodfeeding. Fluorescent screening was performed on L3/L4 larvae or pupae.			
Wild animals were	Wild animals were not used in this study.			
Reporting on sex Data was collected	Data was collected and is reported separately for each sex of Cas9 bearing FO/F1.			
Field-collected samples No field collected	No field collected samples were used in this study.			
Ethics oversight No ethical oversig	No ethical oversight is required for mosquitoes, however this work was approved by The Biological and Genetic Modification Safety			

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Committee.